{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for nonoxynol root_names_name in Any Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2021
Source:
Varecell Intensive Liposome Serum by D&S Cosmedique Co.Ltd
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT04265950: Phase 4 Interventional Active, not recruiting HIV Infection
(2022)
Source URL:
First approved in 2014
Source:
BLA125508
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT04265950: Phase 4 Interventional Active, not recruiting HIV Infection
(2022)
Source URL:
First approved in 2014
Source:
BLA125508
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT04265950: Phase 4 Interventional Active, not recruiting HIV Infection
(2022)
Source URL:
First approved in 2014
Source:
BLA125508
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT04265950: Phase 4 Interventional Active, not recruiting HIV Infection
(2022)
Source URL:
First approved in 2014
Source:
BLA125508
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT04265950: Phase 4 Interventional Active, not recruiting HIV Infection
(2022)
Source URL:
First approved in 2014
Source:
BLA125508
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Active Firming Serum by Jafra cosmetics International
(2019)
Source URL:
First approved in 2011
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT03051516: Phase 4 Interventional Terminated High Grade Anal Canal Intraepithelial Neoplasia
(2017)
Source URL:
First approved in 2006
Source:
BLA125126
Source URL:
Class:
PROTEIN
